Watch out for this new invasive tick. It could saddle you with a little-known, debilitating infection
In May, scientists at the Connecticut Agricultural Experiment Station in New Haven discovered for the first time that the longhorned tick had become a carrier for the bacteria that causes the Ehrlichiosis infection. With cases already on the rise, that was a big cause of concern.
'I am afraid to say that it is a storm brewing,' said Goudarz Molaei, the director of the lab's tick-testing program. 'Climate change eventually will almost eliminate winter in our region. And this tick, like other tick species, will be active year round.'
Warming temperatures, which have already translated into shorter winters, allow the longhorned tick and other tick species to wake up early from hibernation, increasing the risk of getting bitten.
The longhorned tick, which is native to East Asia, first invaded places like Australia, New Zealand and the Pacific Islands. It has now been detected in at least 21 states in the U.S. with Michigan reporting its first sighting at the end of June. Researchers aren't sure how the tick made it to the U.S., but it's likely it arrived on the backs of imported livestock or other animals.
In 2017, scientists identified the country's first longhorned tick in New Jersey, though it's likely the species has been in the U.S. since at least 2010.
'The fact it was here for so long without us actually knowing about it was really a wakeup call,' said Dana Price, an associate research professor in the department of entomology at Rutgers University.
Modeling indicates areas from southern Canada throughout the continental U.S. are environmentally suitable to the longhorned tick.
That means the threat is two-fold: The longhorned's geographic range is expanding and so is the time that they're active and able to transmit disease, scientists said.
Ehrlichiosis is becoming so prevalent that there is a region of the country unofficially named after it: The 'Ehrlichiosis Belt' stretches from as far north as Connecticut and New York to as far west as Arkansas.
The lone star and blacklegged ticks have long carried Ehrlichia chaffeensis, the bacteria that causes Ehrlichiosis. The infection sends about 60% of patients to the hospital and claims the lives of about 1 in 100 patients, according to the Center for Disease Control and Prevention. Infected individuals will typically experience fever, chills, muscle aches, headaches and fatigue one to two weeks after being bitten. But if people aren't treated quickly, the infection can sometimes lead to brain and nervous system damage, respiratory failure, uncontrolled bleeding and organ failure.
The number of Ehrlichiosis cases has risen steadily since 2000 when the CDC reported 200 cases of Ehrlichiosis compared with 2,093 in 2019. Studies suggest that the number of annual Ehrlichiosis cases are grossly underreported with one study from Rutgers University researchers saying 99% of cases go undetected.
The CDC reported earlier this month that there have been more emergency room visits in July for tick bites than the past eight Julys. In early July, officials closed Pleasure Beach, a popular swim spot in Bridgeport, Connecticut, for the summer after discovering an infestation of several tick species including the longhorned tick.
Manisha Juthani, the commissioner of the Connecticut Department of Public Health, said that as climate change makes 'tick season' less predictable, Connecticut residents should take precautions like wearing long pants, tucking them into their socks and conducting tick checks on family members and pets after being outdoors for extended periods of time.
'The reality is that with the changes we're seeing in climate, we have to be more prepared and more aware of the infections and the pathogens that we can be exposed to by being outside and potentially being aware of the things that can really cause the most harm to people,' Juthani said.
While longhorned ticks often prefer the blood of livestock to humans, entomologists say their unique biology makes them a formidable public health hazard. They can establish populations of thousands from a single female because, like bees, they have the ability to reproduce without a mate.
They can also ingest and become carriers for pathogens typically carried by other tick species if they happen to feed on the same host. The process, known as co-feeding transmission, is common among most tick species.
Molaei said his recent discovery of the Ehrlichiosis-causing bacteria in the longhorned tick raises concerns about what other pathogens the tick may be able to contract and transmit to humans. The longhorned tick and the lone star tick, one of the original carriers of ehrlichia, both feed on similar hosts, like white-tailed deer.
'We live in this part of the world with several important tick species, and we have to learn how to live with this many ticks,' Molaei said. 'And the key is to protect ourselves.'
The World Health Organization reports that more than 17% of infectious diseases globally are transmitted through vectors, intermediary animals that ferry viruses, bacteria and other pathogens from one animal to the next. Tick-borne diseases in the U.S. accounted for 77% of vector-borne disease reports from 2004 to 2016, with cases more than doubling in the last 13 years, according to data collected by the CDC.
Jennifer Platt was bitten by a tick during that time. She contracted Ehrlichiosis from a tick bite in North Carolina in the summer of 2011.
When she couldn't pick up and carry her 2-year-old son, her friend, who is a nurse, suggested she go to the hospital immediately. The friend suspected Platt might have a tick-borne infection.
Platt was sick and on antibiotics for months after her diagnosis. Her shoulder locked due to the infection — a rare but contractable chronic symptom of tick-borne disease — leading to months of physical therapy and putting her out of work for three months.
It took her more than a year to fully recover from the lasting impacts of the infection.
'The best way I'd describe it,' she said, 'is I felt like death.'
A few years after she started feeling better, she was diagnosed with Lyme and Babesiosis diseases — which she attributes to the same tick bite.
Platt, who co-founded the advocacy nonprofit Tick-Borne Conditions United, said she hopes the recent discovery of the Ehrlichia bacteria in the longhorned tick will help raise awareness among doctors and the general public about the threat of tick-borne diseases, especially little-known ones like Ehrlichiosis.
'My mission in life is to support people in being who they are,' Platt said. 'And if you're sick from a tick-borne disease, you can't be who you are.'
This article was originally published on NBCNews.com
Solve the daily Crossword
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
UnitedHealth Stock Soars as Warren Buffett's Berkshire Hathaway Discloses $1.57B Stake
UnitedHealth Group (UNH) stock has been a major underperformer in 2025, with UNH down nearly 50% year-to-date amid rising medical costs, regulatory scrutiny, and a Department of Justice investigation into billing practices. However, the company received a major vote of confidence after the closing bell today, when Warren Buffett's Berkshire Hathaway (BRK.A) (BRK.B) disclosed a substantial new position in UnitedHealth totaling 5.04 million shares, valued at approximately $1.57 billion. As a result, UNH stock has surged over 8% in after-hours trading. That puts UnitedHealth on pace to challenge its overhead 50-day moving average in Friday's session. The shares haven't closed above this descending trendline since mid-April. More News from Barchart 1 'Strong Buy' Dividend Stock to Buy to Protect Your Portfolio After Hitting 30th 52-Week Low, Is Adobe Too Cheap to Ignore? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! Why Did Buffett Buy UNH Stock? Valued at $246 billion by market cap, UnitedHealth maintains its position as America's largest health insurer. Despite operational headwinds, the company has maintained its quarterly dividend of $2.21 per share. UNH now yields approximately 3.25%, demonstrating its commitment to shareholder returns and financial stability. Plus, after its steep selloff this year, the stock's current valuation of 11.5 times projected 2027 earnings is significantly below historical averages - suggesting the market may be pricing in an overly pessimistic outlook. What's the Forecast for UNH Stock? Management anticipates a return to growth in 2026 as premium pricing adjustments take effect to offset higher medical costs, particularly in Medicare Advantage plans. Recent trading sessions have shown signs of positive momentum for UNH, with shares rising approximately 11% over the past 5 days as part of a broader rotation into beaten-down healthcare stocks - though the name remains well off its previous highs. Along with Buffett, Wall Street maintains a generally positive outlook on the beaten-down stock, which has a consensus 'Moderate Buy' recommendation. JPMorgan recently reiterated a 'Buy' rating and set a $310 price target for UNH, suggesting about 14% expected upside potential from Thursday's close. This article was created with the support of automated content tools from our partners at Together, our financial data and AI solutions help us to deliver more informed market headline analysis to readers faster than ever. On the date of publication, Elizabeth H. Volk did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025
New York, New York--(Newsfile Corp. - August 14, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will report second quarter 2025 financial results ended June 30, 2025 and provide a business update on the morning of Tuesday, August 19, 2025. About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher that it could then sell. OST-HER2 has completed a Phase 1 clinical study primarily in breast cancer patients, in addition to showing preclinical efficacy data in various models of breast cancer. OST-HER2 has been conditionally approved by the U.S. Department of Agriculture for the treatment of canines with osteosarcoma. In addition, OS Therapies is advancing its next-generation Antibody Drug Conjugate (ADC) and Drug Conjugates (DC), known as tunable ADC (tADC), which features tunable, tailored antibody-linker-payload candidates. This platform leverages the Company's proprietary silicone Si-Linker and Conditionally Active Payload (CAP) technology, enabling the delivery of multiple payloads per linker. For more information, please visit Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute forward-looking statements within the meaning of the federal securities laws. These forward-looking statements and terms such as "anticipate," "expect," "intend," "may," "will," "should" or other comparable terms involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of OS Therapies and members of its management, as well as the assumptions on which such statements are based. OS Therapies cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to the risks and uncertainties described in "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and other subsequent documents the Company files with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by the federal securities laws, OS Therapies specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. OS Therapies Contact Information:Investor RelationsHarrison Seidner, PhDWaterSeid PartnersOSTX@ Public RelationsStephanie ChenElev8 New Mediastephanie@ To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
22 minutes ago
- Yahoo
Costco says it won't sell mifepristone abortion pill
Costco will not sell the abortion pill mifepristone at its pharmacy locations, the shopping club told CBS News. The wholesaler said its decision not to sell the prescription medication was based on a "lack of demand from our members and other patients." "They generally have the drug dispensed by their medical providers," Costco said in a statement to CBS News. Costco's position on the abortion pill, which was first reported by Bloomberg, was praised by a conservative religious coalition, called the Alliance Defending Freedom (ADF), an anti-abortion advocacy group that had urged Costco not to sell mifepristone. "We applaud Costco for doing the right thing by its shareholders and resisting activist calls to sell abortion drugs," ADF's legal counsel Michael Ross said in a statement Thursday. "Retailers like Costco keep their doors open by selling a lifetime of purchases to families, both large and small. They have nothing to gain and much to lose by becoming abortion dispensaries." Mifepristone, first approved by the Food and Drug Administration in 2000, is part of a two-step regimen with misoprostol used to end a pregnancy through 10 weeks. It is used in over half of all abortions in the U.S., according to research from the Guttmacher Institute. Passenger arrested after allegedly causing disturbance midair and forcing flight to divert Tropical Storm Erin expected to become a major hurricane When could Tropical Storm Erin become a hurricane? Solve the daily Crossword